Moleculin Announces Dosing of First Subject in Italy for Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)
HOUSTON, March 1, 2023 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced the first subject has been...
Moleculin Announces Final Topline Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Results align with the overall safety profile of Annamycin - Final cohort demonstrated an 80% overall response rate (ORR) in elderly subjects ( 60 years old) - No cardiotoxicity demonstrated in any study subject - The median number of prior therapies for all...
Moleculin to Present at the Virtual Investor 2023 Companies to Watch Event
Live video webcast on Tuesday, January 17th at 9:00 AM ET HOUSTON, Jan. 5, 2023 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant...
Moleculin Receives Approval in Italy to Conduct Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)
- Ongoing efforts to open additional clinical sites in Poland and to gain approval to proceed in other European countries - First subject treated in Italy expected in the first quarter of 2023 HOUSTON, Dec. 21, 2022 -- Moleculin Biotech, Inc., (Nasdaq: MBRX)...
Moleculin Reports 80% Overall Response Rate in Final Cohort of Phase 1 Single Agent Trial of Annamycin for the Treatment of Acute Myeloid Leukemia (AML)
Preliminary efficacy updated to 80% overall response rate (ORR) demonstrated in single agent AML trial following database lock Next generation anthracycline, Annamycin, has demonstrated both safety and promising early activity across multiple clinical studies with...
Moleculin Granted FDA Fast Track Designation of WP1122 for the Treatment of Glioblastoma Multiforme
HOUSTON, Dec. 7, 2022 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the U.S. Food and...
Moleculin Reports Third Quarter 2022 Financial Results and Provides Pipeline Update
- Continued execution across clinical and preclinical development programs - Three Phase 1b/2 clinical studies with enrollment or dosing now underway - Sufficient capital to fund operations beyond mid-2024 - Company to host conference call and webcast today at 5:00 PM...
Moleculin to Report Third Quarter 2022 Financial Results on November 10, 2022 and Host Inaugural Quarterly Conference Call and Webcast
HOUSTON, Nov. 7, 2022 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it will report its...
Moleculin Provides Update on Second Multiple Ascending Dose (MAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK
Company enters what it expects to be the final MAD cohort in the first-in-human Phase 1a designed to establish a maximum tolerated dose (MTD) HOUSTON, Oct. 14, 2022 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage...
Moleculin Biotech WP1122 Portfolio Compound, WP1096, Selected for NIAID-Funded Animal Studies as Novel Potential Antiviral
- Preclinical work being conducted is intended to validate in vitro findings in established animal models to determine if further preclinical development and human clinical trials are warranted - Hemorrhagic fever arenaviruses (HFA) represent area of significant unmet...